Clinical Trial Update: Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of lenvatinib and everolimus in renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Afinitor (everolimus)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Yousef Zakharia | Conditions: Renal Cell Carcinoma | Phase 1 | Status: COMPLETED